Panitumumab N01

帕妥尤单抗N01

Report date: 2025/12/12 14:21:11

Base Information

Drug NamePanitumumab N01
Drug Alias Name重组抗EGFR全人单克隆抗体（齐鲁制药）重组抗EGFR全人单抗（齐鲁制药）帕尼单抗安可泽QL-1203 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursColorectal Neoplasms
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/12/03
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A